Inventiva S.A.
IVA
Rank in Stocks
#9180
Inventiva S.A. is a biopharmaceutical firm currently in the clinical... Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments. Their primary drug candidate, Lanifibranor, has successfully concluded Phase IIb clinical trials for the management of NASH. Furthermore, the company is advancing Odiparcil, a compound that has finished Phase IIa clinical testing specifically for treating the MPS VI subtype. Beyond these, Inventiva maintains a development pipeline featuring several early-stage projects targeting oncology and other medical conditions. Strategic partnerships are in place with AbbVie to address autoimmune diseases, and with Boehringer Ingelheim International GmbH for innovating therapies for idiopathic pulmonary fibrosis. Established in 2011, Inventiva S.A. operates from its headquarters in Daix, France.
Share Price
$4.31
Last synced: 2026-11-09
Market Cap
$893.57M
Change (1 day)
1.73%
Change (1 year)
-3.88%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Inventiva S.A. (IVA)
Category
Healthcare
EPS for Inventiva S.A. (IVA)
EPS as of June 2026 TTM: $-0.60
According to Inventiva S.A.'s latest financial reports, its current EPS (TTM) is $-0.60. At the end of 2025 the company had an EPS of $-2.14, an increase over its 2024 EPS of $-3.68.
EPS history for Inventiva S.A. from 2013 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.60 | -71.86% |
| 2025 | $-2.14 | -42.03% |
| 2024 | $-3.68 | 37.13% |
| 2023 | $-2.69 | 91.17% |
| 2022 | $-1.41 | -2.70% |
| 2021 | $-1.44 | 19.78% |
| 2020 | $-1.21 | -16.04% |
| 2019 | $-1.44 | -23.80% |
| 2018 | $-1.88 | 41.50% |
| 2017 | $-1.33 | 181.29% |
| 2016 | $-0.47 | -50.44% |
| 2015 | $-0.96 | 5.29% |
| 2014 | $-0.91 | -7.06% |
| 2013 | $-0.98 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -2,700.46% |
US
|
|
| $-7.07 | 1,074.03% |
US
|
|
| $-5.29 | 778.45% |
AU
|
|
| $12.88 | -2,238.84% |
BE
|
|
| $21.56 | -3,680.21% |
NL
|
Questions about Inventiva S.A.'s earnings per share (EPS)
What is Inventiva S.A.'s earnings per share (EPS)?
Inventiva S.A.'s earnings per share (EPS) over the last twelve months is $-0.60, as of Jun 2026.
What was Inventiva S.A.'s earnings per share (EPS) in 2025?
In 2025, Inventiva S.A.'s earnings per share (EPS) was $-2.14, compared with $-3.68 in 2024.
How has Inventiva S.A.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Inventiva S.A.'s earnings per share (EPS) was highest in 2020 ($-1.21) and lowest in 2024 ($-3.68).
How does Inventiva S.A.'s earnings per share (EPS) compare with similar companies?
Inventiva S.A.'s earnings per share (EPS) ($-0.60) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.